1-2 of 2
Jennifer Crombie
Close
Sort by
Journal Articles

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Clinical Trials & Observations
Inhye E. Ahn, Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker, Robert Black, Josie Montegaard, Alvaro Alencar, Leyla Shune, Mohammad Omaira, Caron A. Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer Crombie, David C. Fisher, Ann S. LaCasce, Jon Arnason, Ephraim P. Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2024) 8 (4): 832–841.
https://doi.org/10.1182/bloodadvances.2023011574
Published: 2024
Includes: Supplemental data
Journal Articles

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Clinical Trials & Observations
Reid W. Merryman, Natasha Edwin, Robert Redd, Jad Bsat, Matthew Chase, Ann LaCasce, Arnold Freedman, Caron Jacobson, David Fisher, Samuel Ng, Jennifer Crombie, Austin Kim, Oreofe Odejide, Matthew S. Davids, Jennifer R. Brown, Heather Jacene, Amanda Cashen, Nancy L. Bartlett, Neha Mehta-Shah, Armin Ghobadi, Brad Kahl, Robin Joyce, Philippe Armand, Eric Jacobsen
Journal: Blood Advances
Blood Adv (2020) 4 (5): 858–867.
https://doi.org/10.1182/bloodadvances.2019001355
Published: 2020
Includes: Supplemental data